Introduction
Low dosages of aspirin [1, 2] and ingestion of certain fish oils [3] [4] [5] [6] have recently been touted as having some value in preventing cardiovascular disease. Aspirin is a nonsteroidal anti-inflammatory drug which exerts its action by inhibiting the synthesis of prostaglandins. The abundant w)3 polyunsaturated fatty acids of fish oils derived from cod and salmon also affect the synthesis of prostaglandins, as well as the synthesis of the leukotrienes and related hydroxy fatty acids; the effects of 3 fatty acids on prostaglandin and leukotriene synthesis result from the ability of O3 fatty acids to replace the more common wo6 polyunsaturated fatty acids at the sn-2 position of glycerophospholipids, which are precursors of the eicosanoids. Actually, the benefits of prophylactic use of aspirin and fish oils by healthy individuals are largely unproven. For most people, the minuses of aspirin ingestion probably outweigh the pluses [7] [8] [9] . However, there are real possibilities that changing the normal patterns of eicosanoid production can be useful in ameliorating certain forms of cardiovascular disease [7] [8] [9] [10] [11] [12] [13] [14] [15] , osteoporosis [16, 17] , and arthritis [18] . Certainly, simple aspirin ingestion is already established as a useful treatment for unstable angina [14, 15] .
The prostaglandins, leukotrienes and related hydroxy fatty acids are members of a group of compounds collectively known as the 'eicosanoids'. This review is designed to provide an overview of the eicosanoid area. I will begin by indicating what compounds are considered to be eicosanoids; I will then proceed to a discussion of the pathways involved in the biosynthesis of these compounds; and finally, I will conclude by discussing how eicosanoids act at the molecular level to elicit their effects. I plan to place particular emphasis on discussing the biochemical mechanisms of action of eicosanoids, since this topic has generally been given little attention. I plan to develop the concept that all the various biological actions of eicosanoids can be understood as being initiated by the interaction of an eicosanoid with a receptor which is coupled to a guanine nucleotide regulatory (G) protein.
What are eicosanoids and where are they found?
First, some definitions. The term 'eicosanoid ' has evolved to denote a large, and still growing, family of oxygenated C20 fatty acids (Fig. 1) . The eicosanoid family is made up of three clans, which include the prostanoids (prostaglandins and thromboxanes) which are synthesized via the 'cyclo-oxygenase' pathway, the leukotrienes and certain mono-, di-and tri-hydroxy acids which are formed via 'lipoxygenase' pathways, and the epoxides which are formed by a cytochrome P-450 ' [3, 5, 20] , the well-known 'fish oil' fatty acid (i.e. 'EPA') which is a member of the w3 family. Leukotrienes, but not prostaglandins or thromboxanes, can also be synthesized from 5,8,11 -eicosatrienoic acid, an w)9 fatty acid which accumulates in essential fatty acid deficiency [23] . The major precursor in most mammalian systems is the most abundant C20 polyunsaturate, arachidonic acid (Fig. 1) . Prostanoids and lipoxygenase products of the eicosanoid family are formed by both vertebrates and invertebrates, but not by plants or bacteria which lack appropriate polyunsaturated C20 fatty acid precursors [24, 25] .
A limitation of the term 'eicosanoid' is that certain C18 and C22 fatty acids, including octadecadienoic acid (linoleic acid, 18:2w)6), docosapentaenoic acid (adrenic acid, 22: 5w6) and docosahexaenoic acid (22: 6w3) can be converted to eicosanoid homologues [20, 24, 26] which are not, strictly speaking, eicosanoids. Oxygenated C18 fatty acid products relate,d to the eicosanoids are also formed from linoleic acid by plants via plant lipoxygenases [27, 28] . The lipoxygenase pathways in plants and animals are related. Rat 5-lipoxygenase has marked sequence similarities to the soybean 15-lipoxygenase [28, 29] . My description of the eicosanoids will be limited to the cyclooxygenase and lipoxygenase pathways. The epoxygenase pathway has received considerable attention over the past several years and certain epoxygenase products clearly have potent biological activities, including effects on platelet aggregation and ion and water transport [30] [31] [32] [33] [34] [36] [37] [38] [39] , while other cells respond to these or other agents such as angiotensin II [40] , bradykinin [40] [41] [42] , and [arginine]vasopressin (AVP) [42] [43] [44] . An [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . However, prostanoid formation can also be elicited by mechanical stresses on cells, such as shear forces acting on vascular endothelial cells [47] , and responses to these stresses may not be receptor-mediated. Arachidonate release happens relatively quickly (i.e. in 5-60 s), and is typically accompanied by turnover of inositol-containing phospholipids [36] [37] [38] [39] 48, 49] . In fact, some of the arachidonate used for prostanoid formation may be derived from the sequential hydrolysis of phosphoinositides by phospholipase C and diacylglycerol lipase [36, 50] ; however, the major sources of released arachidonate are probably the most abundant glycerophospholipids, phosphatidylcholine and phosphatidylethanolamine, and the key enzyme is probably a phospholipase A2 such as the one from the P388D1 macrophage line described by Dennis and his coworkers, which is sensitive to specific inhibition by arachidonic acid [50] [51] [52] .
Prostaglandin endoperoxide synthesis. Conversion of arachidonic acid to the prostaglandin endoperoxide PGH2 is mediated by PGG/H synthase, an integral membrane protein found in greatest abundance in the endoplasmic reticulum of prostanoid-forming cells [35, 53, 54] . The detergent-solubilized enzyme appears to be a dimer composed of identical subunits [55, 56] . PGG/H synthase exhibits two distinct catalytic activities, a bis-oxygenase (cyclo-oxygenase) involved in PGG2 formation and a hydroperoxidase mediating a net twoelectron reduction of the 1 5-hydroperoxyl group of PGG2 to yield PGH2 [57, 58] . Both activities require haem [55, 57, [59] [60] [61] . The cyclo-oxygenase, but not the hydroperoxidase activity, is specifically inhibited by aspirin and related nonsteroidal anti-inflammatory drugs [62] [63] [64] . Upon exposure to aspirin, the enzyme is O-acetylated at a serine residue located 70 amino acids from the C-terminus [65, 66] ; acetylation leads to irreversible cyclo-oxygenase inhibition [67] , and thus, new enzyme synthesis is required before more prostanoids can be produced. Indomethacin, meclofenamate and flurbiprofen also cause irreversible inactivation of the cyclooxygenase activity but apparently without covalent modification of the enzyme [68, 69] . Other common nonsteroidal anti-inflammatory drugs, such as ibuprofen, flufenamic acid, and sulindac, are reversible enzyme inhibitors which are competitive inhibitors of arachidonate binding [68, 70] . The level of PGG/H synthase protein has been shown to be influenced in various cell and organ systems by steroids [71, 72] , growth factors [45, [72] [73] [74] [75] [35, [78] [79] [80] , blood platelets form mainly TxA2 [81] , PGE2 is the major product of collecting tubule cells [43] , and PGF2. is the product of uterine endometrium [71] . In comparison to PGG/H synthase, relatively little is known about the enzymes which catalyse the metabolism of PGH2. Both PGI2 synthase [82, 83] and TxA2 synthase [84, 85] have been purified to homogeneity and both enzymes appear to be related membrane-bound haemoproteins with a cytochrome P-450 chromophore. The levels of PGI2 synthase and PGG/H synthase protein are co-ordinately regulated in endothelial cells by endothelial cell growth factor [74] . This finding indicates that PGI2 synthase and perhaps other PGH2 metabolizing enzymes are regulated in concert with PGG/H synthase.
PGE2 synthesis requires reduced glutathione [86] . The formation of PGE2 is catalysed by several immunologically distinct, membrane-bound PGH-PGE isomerases which lack glutathione S-transferase activity [87] , as well as by several subtypes of soluble glutathione S-transferase [88] . The question of which, if any, of these enzymes is important in PGE2 synthesis in vivo is unresolved. Several soluble proteins with PGH-PGD isomerase activity have also been purified [89] [90] [91] . Recently, a PGF reductase activity has been isolated from lung [92] .
Synthesis of lipoxygenase products. Leukotriene [97, 98] and it has been suggested that this enzyme participates in the formation of lipoxins ( Fig. 1; [93] ). The 5-lipoxygenase pathway has been the lipoxygenase pathway which has received the most attention because this pathway is the one involved in leukotriene formation (Fig. 3) . Thus, 5 [29, 93] . LTA4 can be converted to LTB4 (5S,12R-diHETE) by net addition of water via the action of LTA4 hydrolase [99, 100] or to LTC4by addition of the glutathionyl group at C-6 by the action of a glutathione S-transferase [101] . Leukotrienes containing peptides or amino acids at C-6 are termed peptidoleukotrienes. LTC4 can be cleaved by y-glutamyltranspeptidase to produce LTD4, and LTD4 can be further metabolized to LTE4 by a dipeptidase [101] . LTC4 and LTD4 comprise the major elements of the slow reacting substances of anaphylaxis (SRS-A); LTE4 has about one-tenth the myogenic activity of LTC4 or LTD4 [93] . [112] [113] [114] , and leukotrienes [101, 112, 115, 116] . Prostanoid catabolism begins with oxidation of the 15- hydroxyl group to yield in one step the 1 5-oxo-derivatives which have 10-to 100-fold less activity than the parent compounds. There are different 1 5-hydroxyprostaglandin dehydrogenases specific for different prostanoids. These dehydrogenases are concentrated in the lung, kidney, and placenta [112] [113] [114] . The major urinary metabolites of prostanoids are C16 dicarboxylic acids (i.e. dinor derivatives) which result from w-oxidation and ,-oxidation of the parent 1 5-oxo-13, 14-dihydro catabolites [105, 112] . With the leukotrienes, the first step in catabolism is hydroxylation at C-19 (w-1) or 20 (w), which is followed by oxidation to a dicarboxylic acid and then 8-oxidation [101, 112, 115, 116] . (Fig. 4) . I will emphasize that in the renal collecting tubule and the adjacent thick ascending limb, PGE2 is able to operate through two different receptors -a stimulatory receptor coupled to Gs and involved in activation of adenylate cyclase (i.e. ,ladrenergic-like), and an inhibitory receptor coupled to G, and involved in inhibition of vasopressin-stimulated adenylate cyclase (a2-adrenergic-like). Then, in completing this discussion of eicosanoid action, I will summarize the evidence which suggests that not only PGE2, but all prostanoids and leukotrienes, operate through G protein-linked receptors.
Regulation of whole body water balance depends on drinking (input) and renal water reabsorption (input/output); the final segment of the renal tubule, the collecting tubule, is the site at which water reabsorption is regulated ( Fig. 4; [121] ). Water reabsorption by the collecting tubule is dependent on two factors: (a) the presence of circulating antidiuretic hormone (i.e. AVP) and (b) the existence of an osmotic gradient between the tubule lumen and the surrounding interstitium. The formation of the concentration gradient depends on the action of the ascending thick and thin limbs of Henle's loop (which together comprise the 'diluting segment') which run adjacent, but antiparallel, to the collecting tubule; the diluting segment actively pumps NaCl from the lumen into the interstitium. NaCl reabsorption by this segment is potentiated by AVP. The diluting segment itself is water impermeable, so that NaCl reabsorption by the thick limb results in the formation of both a hyperosmotic interstitium and a hypo-osmotic tubular filtrate. Vol. 259
Physiological effects of PGE2 on the collecting tubule and thick ascending limb. The effect of AVP to cause water reabsorption by the collecting tubule is mediated by cyclic AMP (Fig. 4) ; AVP acts via a stimulatory V2 receptor coupled to a stimulatory guanine nucleotide regulatory protein Gs to cause cyclic AMP synthesis [122] ; elevating intracellular cyclic AMP levels leads to water reabsorption; however, the mechanism by which increases in cyclic AMP are translated into the physiological response of water reabsorption are ill-defined [123, 124] . By using perfused, microdissected segments of rabbit cortical collecting tubule, Grantham & Orloff showed that low concentrations of PGE1 (10-9 M) inhibit the water reabsorbing (i.e. hydro-osmotic) effect of AVP [125] , but that these same concentrations of PGE1 failed to inhibit water reabsorption caused by exogenous cyclic AMP. These results suggested that 10-9 M PGE1 blocked AVP-induced water reabsorption by interfering with AVP-induced cyclic AMP synthesis. Grantham & Orloff then also found a second effect of PGE1; at higher concentrations (10-7 M) PGE1, by itself, stimulated water reabsorption.
Evidence with whole animals strongly suggests that the inhibitory effect of PGE1 (PGE2 has the same effects) seen by Grantham & Orloff with the dissected collecting tubule is physiological. Experimental manoeuvres such as indomethacin treatment [126, 127] or essential fatty acid deficiency [128] which cause decreased renal prostaglandin synthesis result in the formation of a hyperosmotic urine, as would be expected if there were diminished inhibitory control by prostaglandins of the water-reabsorbing effect of AVP. The observations which indicate that PGE2 is actually available in vivo to regulate water reabsorption are: (a) that the collecting tubule is one of only two tubular regions where prostaglandins are synthesized [129] [130] [131] and (b) that the major prostanoid synthesized by the collecting tubule is PGE2 [43, 132] .
AVP can stimulate NaCl reabsorption in the thick ascending limb of Henle's loop, and cyclic AMP also appears to be the second messenger which mediates this effect ( Fig. 4 ; [133] [134] [135] ). Moreover, AVP-induced NaCl reabsorption in the perfused mouse thick limb is attenuated by PGE2 via a pertussis toxin-sensitive mechanism [135] . These results suggested that the immediate biochemical effects of AVP and PGE2 on cyclic AMP metabolism in both the collecting tubule and the thick limb are analogous, although the physiological endpoints -water flow and NaCl reabsorption, respectively -are different.
Cellular effects of PGE2 on the collecting tubule and thick ascending limb. Studies with perfused tubule preparations suggested that PGE derivatives would inhibit AVP-induced cyclic AMP synthesis by both the collecting tubule and the thick limb. This model has now been tested with purified preparations of both collecting tubule cells and thick limb cells [136] [137] [138] . Isolated collecting tubule cells were found to synthesize cyclic AMP in response to AVP, and low concentrations of PGE2 (< 10-8 M) were found to inhibit AVP-induced cyclic AMP accumulation by intact cells (Fig. 4; [137] ). The inhibitory effect of PGE2 was blocked by pretreatment of the cells with pertussis toxin, suggesting a role for an inhibitory guanine nucleotide regulatory protein such as G,. Moreover, PGE2 was found to inhibit AVP-induced adenylate cyclase activity directly in membranes prepared from freshly isolated rabbit cortical collecting tubule cells [137] . Virtually identical results have been obtained with thick limb cells [138] . These inhibitory responses to PGE2, which are analogous to°x2-adrenergic receptor mediated responses of the human platelet to adrenaline, suggested that PGE2 can operate through an inhibitory receptor coupled to G1 to inhibit hormone-stimulated adenylate cyclase in both the collecting tubule and the thick limb.
Higher concentrations of PGE2 () 10' M) caused stimulation of the adenylate cyclase activity in both collecting tubule and thick limb cells [137, 138] . Thus, there is a second PGE response presumably mediated through G.. In the case of the collecting tubule, the increase in cyclic AMP formation induced by PGE2 would explain the observation of Grantham & Orloff [125] that high concentrations of PGE1 stimulate, rather than inhibit water reabsorption.
PGE receptors of collecting tubule and thick limb cells. The inhibitory and stimulatory responses to PGE of collecting tubule and thick limb cells suggest that each cell type possesses two types of PGE receptors, an inhibitory receptor coupled to Gi and a stimulatory receptor coupled to Gs.
There is a [3H]PGE2 binding activity with properties expected for an inhibitory, Gi-linked PGE receptor associated with membranes from the outer medulla of canine and rabbit kidney [139] and purified collecting tubule [140] and thick limb cells [138] . The KD for PGE2 binding to membranes is about 10 nm, a concentration at which PGE2 causes half-maximal inhibition of AVPstimulated cyclic AMP formation [137] . Addition of guanine di-and trinucleotides, but not GMP or adenine nucleotides, causes a highly unusual increase in binding affinity of about 2-fold with no apparent change in B..ax, and this effect of guanine nucleotides on binding is eliminated by treatment of the membranes with pertussis toxin. Substitution at the methyl end of the PGE2 molecule (e.g. 16-phenoxy or 17-phenyl groups) has little effect either on binding or on the ability of PGE2 to inhibit AVP-induced cyclic AMP formation. In fact, sulprostone( 1 6-phenoxy-17,18,1 9,20-tetranor-PGE2 methylsulphonilamide) is equipotent to PGE2 in inhibiting [3H]PGE2 binding to membranes prepared from the collecting tubule [140] and in causing inhibition of AVP-induced cyclic AMP formation by rabbit cortical collecting tubule cells [137] . As will be discussed next, these pharmacological properties are quite different from those characteristic of PGE-induced cyclic AMP formation. Interestingly, the Gi-linked PGE receptor of the collecting tubule and thick limb can be solubilized from the renal medulla with digitonin. This solubilized receptor occurs in a complex with Gi and exhibits PGE2 binding properties very similar to those of the membranebound receptor [139] ; these observations indicate that the coupling of this inhibitory PGE receptor to Gi is direct.
Although PGE2, when used at relatively low concentrations (< 10-8 M), will inhibit AVP-induced cyclic AMP formation by collecting tubule and thick limb cells, higher concentrations of PGE2 actually cause stimulation of cyclic AMP formation [137] . This effect is specific for E series prostanoids, and suggests that there is a stimulatory PGE receptor associated with the collecting tubule and thick limb. Pharmacological The function of PGE2, acting via the stimulatory PGE receptor in the collecting tubule, is unclear. One can speculate that when the collecting tubule is exposed to very high concentrations of AVP, maximal PGE2 synthesis occurs, and that the resulting PGE2, acting via the stimulatory receptor, may transiently augment water reabsorption; however, large increases in cyclic AMP levels in the collecting tubule are known to attenuate PGE2 production, probably by blocking arachidonate release [141] . Thus, the stimulatory PGE receptor may be -part of a feedback mechanism preventing excessive PGE2 formation by the collecting tubule (Fig. 4) . In addition (or alternatively), supramaximal increases in cellular cyclic AMP occurring when collecting tubule or thick limb cells are exposed to high concentrations of both AVP and PGE2 may activate cyclic AMP-dependent receptor kinase activities leading to down-regulation of responses to both agonists [142] .
Eicosanoids act via G protein-linked receptors. A major lesson from studies on the effects of PGE on the renal collecting tubule is that prostanoids can act via receptors which, analogous to adrenergic receptors, are directly coupled to guanine nucleotide regulatory proteins. The question that then arises is whether all eicosanoid actions can be explained as occurring through receptors which are G protein-linked. Since no eicosanoid receptors have been purified to homogeneity for appropriate reconstitution studies with isolated G proteins, the question cannot be answered directly. However, the answer is probably yes, and the reasoning is as follows. An eicosanoid receptor can be considered to be G proteinlinked ifeicosanoid binding is affected by GTP derivatives and/or if addition of the eicosanoid to a plasma membrane preparation stimulates GTPase activity [143] . Based on either criterion, receptors (i.e. binding activities) for eicosanoids which have been tested for these properties qualify (Table 1) .
A two-part summary statement about eicosanoid actions then is that: (a) prostanoids and leukotrienes are local hormones functioning to co-ordinate effects of those other hormones which induce eicosanoid synthesis, and (b) eicosanoids function through G protein-linked receptors to elicit their cellular effects (Fig. 5) Ca2" or K+ channels, or possibly promoting Na+/H+ exchange [144] . The multitude of biological effects produced by eicosanoids can be understood if there are several types of receptors specific for each eicosanoid, with each receptor coupled to a different G protein mediating a different biochemical event. There may even be subtypes of eicosanoid receptors coupled to the same G protein, as appears to be the case with ,B-and a2-adrenergic receptors [145] [146] [147] .
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